Year 2017 / Volume 24 / Number 2

Abstract PDF

Original

Paxiflas®: new FDT combination of tramadol/paracetamol for treating moderate to severe pain

Rev Soc Esp Dolor 2017; 24(2):59-67 / DOI: 10.20986/resed.2017.3565/2017

ABSTRACT

Introduction: Paxiflas® is the combination of tramadol HCl/paracetamol (37.5/325 mg) in fast disintegrating tablets (FDTs), commercialized by Laboratorios Gebro Pharma S.A. The FDTs are intended to be placed in the mouth, where they are rapidly disintegrated without the need of water. They are aimed to active patients who do not have access to drinking water all the time, busy individuals, or those who travel frequently. Moreover, they are especially indicated for individuals with difficulties in swallowing and the elderly and help to improve therapeutic compliance. In addition, the combination combines the rapid action of paracetamol with the longer action of tramadol hydrochloride.

Objectives: To demonstrate the bioequivalence between Paxiflas®, administered with or without water, and tablets of the reference product, Zaldiar®, administered with water, in healthy subjects under fasting conditions.

Material and methods: Open label, balanced, randomized, crossover, single oral dose, 3 treatment, 3 period, 3 sequence, with a washout period of 7 days for subsequent period I and II, and 8 days for period II and III. Subjects were randomized to receive single oral dose (2 tablets) of Paxiflas®, administered without water (product A) or with water (product B), and Zaldiar ® with water. Bioequivalence was considered if the 90 % confidence interval (90 % CI) of geometric mean ratio of Cmax and AUC0-t between test and reference product fell within the range of 80-125 % for (+) tramadol, (-) tramadol, and paracetamol.

The secondary objective was to monitor the safety and tolerability of products A and B.

Results: Bioequivalence was evaluated in 38 subjects for product A and in 39 subjects for product B. Optimal plasma concentration levels of (+) tramadol were achieved at 0.75-3 h

for product A, at 0.5-4 h for product B, and at 0.5-3 h for reference product. In the case of (-) tramadol, plasma levels were achieved at 0.75-3 h for product A, at 0.5-4 h for product B, and at 0.5-3 h for reference product. Finally, plasma levels of paracetamol were achieved at 0.25-2.5 h for the product A, at 0.5-2 h for product B, and at 0.25-2.5 h for reference product. Bioequivalence (90 % CI lying within the acceptable range of 80.00-125.00 %) was met in 38 subjects receiving product A and 39 subjects receiving product B. Tramadol HCl/paracetamol FDTs were well tolerated. A total of 6 adverse events (AEs) were reported during the study (headache, giddiness, pain in abdomen, itching on forearms and thighs, and elevated eosinophil count), of which 3 were expected and possibly related

to the study product. The AEs were mild to moderate in severity. No serious AE was observed during the study.

Discussion: Data from the present study demonstrate the bioequivalence between Paxiflas® FDTs, administered with and without water in different periods, and tablets of Zaldiar®, administered with water, in terms of rate and extent of absorption under fasting condition.

Key words: Bioequivalence, tramadol, paracetamol, fast disintegrating tablets, pain, treatment.

Nuevo comentario

Security code:

Comentarios

No comments in this article

Instrucciones para citar

C. Tornero-Tornero1, J. Galván2, I. García2, M. Boyer3 y J. Orduña Valls1 1Unidad Dolor. Servicio de Anestesiología. Hospital Clínico Universitario. Valencia. 2Departamento Médico. Laboratorios Gebro Pharma S.A. 3Departamento Clínico. Athena Drug Delivery Solutions Pvt Ltd. Paxiflas®: new FDT combination of tramadol/paracetamol for treating moderate to severe pain. Rev Soc Esp Dolor 2017; 24(2):59-67 / DOI: 1020986/resed20173565/2017

Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 47668 veces.
Este artículo ha sido descargado 26 veces.

Estadísticas de Dimensions

Estadísticas de Plum Analytics

Este artículo aun no tiene valoraciones.

Reader rating:

Rate this article:

Send by e-mail

Gestión de Cookies	Nombre	Tipo de Cookie	Función
Google	NID, PREF	Persistente	Personalizar los anuncios que se muestran en los servicios de Google.
Google Analytics	__utma, __utmb, __utmc, __utmz	Persistente	Conocer de forma anónima, nº de visitantes, procedencia, páginas visitadas, etc.